Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
Animals
Antineoplastic Agents, Immunological
/ administration & dosage
B7-H1 Antigen
/ antagonists & inhibitors
Cell Line, Tumor
Cisplatin
/ administration & dosage
Combined Modality Therapy
Cystectomy
Deoxycytidine
/ administration & dosage
Epithelial-Mesenchymal Transition
/ drug effects
Granulocyte-Macrophage Colony-Stimulating Factor
/ administration & dosage
Humans
Margins of Excision
Mice
Neoadjuvant Therapy
Neoplasm Recurrence, Local
/ immunology
Random Allocation
Survival Analysis
Treatment Outcome
Urinary Bladder Neoplasms
/ immunology
Xenograft Model Antitumor Assays
Gemcitabine
bladder neoplasm
colony-stimulating factor
local recurrence
neoadjuvant chemoimmunotherapy
radical cystectomy
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
25
05
2019
revised:
31
07
2019
accepted:
02
08
2019
pubmed:
7
8
2019
medline:
12
10
2019
entrez:
7
8
2019
Statut:
ppublish
Résumé
Despite advances and refinements in surgery and perioperative chemotherapy, there are still unmet medical needs with respect to radical cystectomy for muscle-invasive bladder cancer (MIBC). We investigated the potential benefit of supplementary granulocyte macrophage colony-stimulating factor (GM-CSF) to chemoimmunotherapy with programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis blockade and standard neoadjuvant chemotherapy in bladder cancer. We inoculated 2 × 10
Identifiants
pubmed: 31385407
doi: 10.1111/cas.14158
pmc: PMC6778624
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
CD274 protein, human
0
Deoxycytidine
0W860991D6
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Cisplatin
Q20Q21Q62J
Gemcitabine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3315-3327Subventions
Organisme : JSPS KAKENHI
ID : 16K20159
Organisme : JSPS KAKENHI
ID : 26861290
Organisme : Nara Medical University Grant-in-Aid for Collaborative Research Projects
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Clin Genitourin Cancer. 2017 Feb;15(1):e45-e52
pubmed: 27554584
PLoS One. 2017 Apr 13;12(4):e0175494
pubmed: 28406993
Cancer Immunol Res. 2016 Nov;4(11):948-958
pubmed: 27688020
Protein Cell. 2016 Feb;7(2):130-40
pubmed: 26797765
J Immunol. 2008 Oct 15;181(8):5791-802
pubmed: 18832739
J Clin Oncol. 2004 Jul 15;22(14):2781-9
pubmed: 15199091
Drugs. 2011 May 28;71(8):1093-104
pubmed: 21668044
PLoS One. 2017 Apr 6;12(4):e0174978
pubmed: 28384195
Int J Urol. 2019 Feb;26(2):300-302
pubmed: 30324660
N Engl J Med. 2010 Sep 30;363(14):1324-34
pubmed: 20879881
Eur Urol. 2004 Feb;45(2):176-81
pubmed: 14734003
Cancer Res. 2013 Jan 1;73(1):395-405
pubmed: 23108143
J Clin Oncol. 2005 Jun 20;23(18):4198-214
pubmed: 15961767
J Cancer. 2018 Oct 22;9(23):4374-4381
pubmed: 30519342
Neoplasia. 2016 Oct;18(10):636-646
pubmed: 27690238
BJU Int. 2013 Jun;111(8):1253-60
pubmed: 23331375
Gut. 2019 Nov;68(11):1918-1927
pubmed: 30852560
J Clin Med. 2016 Apr 29;5(5):
pubmed: 27136592
J Urol. 2006 Jun;175(6):2087-91
pubmed: 16697809
Oncology. 2017;93(4):259-269
pubmed: 28647740
Clin Cancer Res. 2017 Oct 15;23(20):6165-6177
pubmed: 28855348
J Clin Oncol. 2003 Jan 1;21(1):99-105
pubmed: 12506177
Oncoimmunology. 2015 Oct 29;5(4):e1101204
pubmed: 27141383
Br J Cancer. 2010 May 25;102(11):1555-77
pubmed: 20502460
Annu Rev Med. 2015;66:97-110
pubmed: 25341012
Gastric Cancer. 2005;8(3):198-201
pubmed: 16086124
Urol Oncol. 2018 Sep;36(9):405-412
pubmed: 29606341
Onco Targets Ther. 2018 Sep 19;11:5973-5989
pubmed: 30275703
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Blood. 1998 Dec 15;92(12):4491-508
pubmed: 9845514
Int J Mol Sci. 2018 Mar 15;19(3):
pubmed: 29543758
J Clin Oncol. 2017 Jul 1;35(19):2117-2124
pubmed: 28375787
Cancer Sci. 2019 Oct;110(10):3315-3327
pubmed: 31385407
J Urol. 1982 Jun;127(6):1233-7
pubmed: 7087044
N Engl J Med. 2003 Aug 28;349(9):859-66
pubmed: 12944571
Int J Mol Sci. 2017 Oct 19;18(10):
pubmed: 29048388
Clin Cancer Res. 1999 Jul;5(7):1738-44
pubmed: 10430077
Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):81-8
pubmed: 22543204
Onco Targets Ther. 2018 May 16;11:2891-2899
pubmed: 29844686
Ann Oncol. 2014 Jun;25(6):1192-8
pubmed: 24669010
World J Urol. 2015 Nov;33(11):1753-61
pubmed: 25663359
J Clin Oncol. 2011 Jun 1;29(16):2171-7
pubmed: 21502557